Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

9.500 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 68.43% to $17.18 during Friday's pre-market session. The market value of their outstanding shares is at $119.6... 
Via Benzinga
News headline image
US Government Agrees To Purchase GSK-Vir Biotech's COVID-19 Antibody Doses Worth $1B ↗
The United States government has signed contracts worth about $1 billion to secure the antibody-based COVID-19 treatment developed by GlaxoSmithKline plc (... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Rockwell Medical (NASDAQ:RMTI) shares rose 47.27% to $0.71 during Wednesday's pre-market session. The company's market cap stands at $66.5 million. The... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Atea Announces Termination of Strategic Collaboration With Roche Atea... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
News headline image
25 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers 17 Education & Technology Group Inc. (NASDAQ: YQ) rose 283.5% to $3.16 in pre-market trading. 17 Education & Technology, earlier during the month, reported a $10... 
Via Benzinga
News headline image
GSK, Vir's Intramuscularly-Administered Sotrovimab Shows Efficacy At Par With IV Route In COVID-19 ↗
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered... 
Via Benzinga
News headline image
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded... 
Via Benzinga
News headline image
3 Vaccine Stocks With Big Opportunities Outside of COVID-19 ↗
For most of the past two years, all the focus has been on the coronavirus, but these biotechs have big plans to develop inoculations against other diseases, too. 
Via The Motley Fool
News headline image
Why Vir Biotechnology Stock Is Sliding Today ↗
Efficacy results for oral antivirals from Pfizer and Merck are weighing heavily on Vir today. 
Via The Motley Fool
News headline image
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
News headline image
GlaxoSmithKline Drops Research On Otilimab In COVID-19 ↗
GlaxoSmithKline Plc (NYSE: GSK), in its Q3 earnings release, revealed that it is stopping the development of otilimab in COVID-19 in patients who are at least 70 years... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2021 ↗
Upgrades According to Wedbush, the prior rating for Regions Financial Corp (NYSE: 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
Wells Fargo boosted Bank of America Corporation (NYSE:B... 
Via Benzinga
News headline image
GlaxoSmithKline: My Top Value Stock For The Week ↗
GSK, one of the biggest pharmaceuticals companies in the world, is seeing a lot of success with new drugs and plenty more in the pipeline. Better yet for would-be investors, the stock is still very... 
Via Talk Markets
News headline image
Moderna Slapped With Sell Rating Despite CDC Authorization For Covid Boosters ↗
The CDC authorized boosters from J&J, Moderna and a mix-and-match approach. 
Via Investor's Business Daily
News headline image
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies ↗
Companies working on sorely needed Covid treatments are innovating to keep up. 
Via Investor's Business Daily
News headline image
AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial ↗
AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares increased by 46.15% to $3.61 during Wednesday's pre-market session. The company's market cap stands at $136.9... 
Via Benzinga
News headline image
Tesla and Merck Give Investors Some Hope ↗
Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate... 
Via Benzinga
News headline image
54 Biggest Movers From Friday ↗
Check out these big penny stock gainers and losers Losers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to close at $7.10 on Friday. Spire Global, Inc.... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Biomerica Shares Spike Higher ↗
Toward the end of trading Friday, the Dow traded up 1.49% to 34,346.53 while the NASDAQ rose 0.75% to 14,556.92. The S&P also rose, gaining 1.18% to 4,358.52. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Biomerica (NASDAQ:BMRA) stock moved upwards by 39.33% to $6.27 during Friday's regular session. As of 12:30 EST, Biomerica's stock is trading at a volume... 
Via Benzinga
News headline image
Merck Stock Surges Into Buy Zone As Covid Pill Reduces Risk Of Death, Hospitalization ↗
Merck said its Covid pill, molnupiravir, cut the risk of death and hospitalization by half. 
Via Investor's Business Daily
Topics Stocks
News headline image
Glaxo - Vir Biotech's COVID Treatment Approved In Japan ↗
Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
News headline image
Why Vir Biotechnology Stock Is Sinking This Week ↗
Shares fell after an analyst's downgrade. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021 ↗
Upgrades Argus Research upgraded the previous rating for Simon Property Group Inc (NYSE: 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.